Stockscreener 앱 받기
1.14%
전일 마감가:
$24.66
열려 있는:
$24.39
하루 거래량:
103.35M
Relative Volume:
1.90
시가총액:
$138.56B
수익:
$63.83B
순이익/손실:
$10.77B
주가수익비율:
12.96
EPS:
1.8799
순현금흐름:
$12.44B
1주 성능:
-0.49%
1개월 성능:
-10.92%
6개월 성능:
+0.74%
1년 성능:
-12.18%
1일 변동 폭
$24.31
$25.20
1주일 범위
$24.15
$25.20
52주 변동 폭
$20.91
$28.00
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
PFE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.37 | 140.21B | 63.83B | 10.77B | 12.44B | 1.8799 |
|
LLY
Lilly Eli Co
|
897.25 | 802.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
187.14 | 448.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
215.03 | 374.44B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
124.73 | 237.66B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.36 | 206.04B | 63.99B | 19.05B | 14.72B | 7.5596 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera - Barron's
Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera - Proactive Investors
Transcript : Pfizer Inc., Q3 2025 Earnings Call, Nov 04, 2025 - MarketScreener
Delaware court won't rule on Pfizer/Novo battle for Metsera today - Seeking Alpha
Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo - Reuters
Pfizer : Quarterly Corporate PerformanceThird Quarter 2025 Prepared Remarks - MarketScreener
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up - Yahoo Finance
Pfizer reports strong Q3 earnings, raises full-year profit guidance - Proactive financial news
Pfizer Inc. Reaffirms Earnings Guidance for the Full Year of 2025 - MarketScreener
Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer - MSN
Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup - The Wall Street Journal
Pfizer & Novo boost Metsera bids, Hertz stock skyrockets - Yahoo Finance
Pfizer’s Q3 Earnings Beat on Top and Bottom Lines - Yahoo Finance
Pfizer, Novo Boost Bids for Obesity Drugmaker Metsera in Takeover Saga - Bloomberg.com
Novo Nordisk Hikes Metsera Bid to up to $10B in Competition With Rival Pfizer - U.S. News & World Report
Global markets live: Tesla, Amazon, Palantir, Pfizer, Merck… - MarketScreener
Pfizer Inc. 2025 Q3ResultsEarnings Call Presentation (NYSE:PFE) 2025-11-04 - Seeking Alpha
Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools - Zacks Investment Research
Novo, Pfizer Boost Metsera Bids in Obesity Startup Battle - Bloomberg.com
Pfizer Stock Falls on Third-Quarter Earnings. What Covid-19 Has to Do With It. - Barron's
Pfizer says drug pricing agreement with US government has no impact on 2025 guidance - MarketScreener
Pfizer’s revenue falls as COVID sales and vaccine recommendations continue to fade - MSN
Here's What Key Metrics Tell Us About Pfizer (PFE) Q3 Earnings - Yahoo! Finance Singapore
Pfizer Boosts Profit View While Chasing Obesity Startup Metsera - Bloomberg.com
Dow Dips Over 400 Points; Pfizer Earnings Top Estimates - Benzinga
Pfizer COVID-19 vaccine sales tumble after government guidance on the shots narrows - Yahoo Finance
Hyperlipidemia Drugs Market Report 2025: $24.74 Industry Led by Pfizer, Merck & AbbVie, With Asia-Pacific Poised for Strong Growth Amid Trade-Driven Supply Chain ShiftsGlobal Forecast to 2034 - Yahoo Finance
Metsera gets higher bids from Novo Nordisk, Pfizer in bidding war (MTSR:NASDAQ) - Seeking Alpha
Metsera Gets Revised Bids From Pfizer, Novo Nordisk: Here’s Why It Matters - Stocktwits
Both Novo Nordisk and Pfizer have adjusted their bids for Metsera. - MarketScreener
Pfizer's Q3: Stagnation Continues (NYSE:PFE) - Seeking Alpha
Pfizer's Core Drugs Offset COVID Revenue Drop, Lifts 2025 Profit Outlook Despite Tariffs - Benzinga
Novo Nordisk sweetens bid for Metsera with an offer of up to $10 billion - Reuters
Pfizer (PFE): Is There Untapped Value in Today’s Evolving Pharmaceutical Market? - Yahoo Finance
Pfizer Q3 Results Signal Shift From Covid Windfall to Obesity-Driven Growth Path - Investing.com
Palantir's post-earnings drag, Uber sinks, Pfizer earnings - Yahoo Finance
Pfizer Inc. Stock (PFE) Opinions on Recent Earnings Report - Quiver Quantitative
Pfizer’s (NYSE:PFE) Q3 Earnings Results: Revenue In Line With Expectations - Yahoo Finance
PFIZER INC : JP Morgan reaffirms its Neutral rating - MarketScreener
Earnings from Uber, Shopify, Spotify and Pfizer: Market Movers - Yahoo Finance
Pfizer Delivers A Win Even As Covid Revenues Fall - Finimize
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (November 2025) - 24/7 Wall St.
Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance
Pfizer: Q3 Earnings Snapshot - San Francisco Chronicle
Pfizer boosts profit view as it battles for obesity startup - The Edge Malaysia
Pfizer's $4.9 Billion Gamble: Inside Its Legal War to Reclaim the Obesity Market - Yahoo Finance
Pfizer Q3 Adjusted Earnings, Revenue Fall; Annual Adjusted EPS Outlook Upgraded - MarketScreener
Earnings Flash (PFE) Pfizer Inc. Reports Q3 Revenue $16.65B, vs. FactSet Est of $16.50B - MarketScreener
Earnings Flash (PFE) Pfizer Inc. Posts Q3 Adjusted EPS $0.87 per Share, vs. FactSet Est of $0.63 - MarketScreener
Pfizer raises 2025 profit forecast for second quarter in a row - Reuters
Pfizer raises earnings outlook as COVID vaccine sales drive Q3 beat - Seeking Alpha
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
0.01%
자본화:
|
볼륨(24시간):